United States of America v. Sanofi Aventis U.S. LLC, et al.Annotate this Case
The Third Circuit Court of Appeals certified a series of questions of law to the Delaware Supreme Court. The Questions arose in connection with the prosecution of a qui tam action under the False Claims Act (“FCA”), In re: Plavix Marketing, Sales Practices and Products Liability Litigation (No. II), brought against Sanofi-Aventis U.S. LLC, Sanofi-Aventis U.S. Services, Inc., Aventis, Inc., Aventis Pharmaceuticals, Inc., Bristol-Myers Squibb Company, and Bristol-Myers Squibb Pharmaceuticals Holding Partnership (together, “Defendants”). The relator bringing the action, on behalf of the United States and several states, is JKJ Partnership 2011 LLP, a Delaware limited liability partnership. The partnership consisted of three individuals who allegedly were each an “original source” of knowledge upon which the allegations against Defendants were based. The Questions arose when one of the partners was replaced by another partner, and an amended complaint was filed shortly thereafter. Upon the filing of the amended complaint, the Defendants moved to dismiss, alleging, in-part, that replacing the partner was impermissible the under the FCA’s “first-to-file” bar. The United States District Court for the District of New Jersey (the “District Court”) granted the motion on that ground. The partnership appealed to the Third Circuit, which, in turn, certified the Questions that related to the “construction or application of” a Delaware statute “which has not been, but needed to be settled by the Delaware Supreme Court.